Cantor Fitzgerald Comments on NeuroPace FY2025 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for NeuroPace in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.79) per share for the year. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share.

Several other research firms have also recently commented on NPCE. JPMorgan Chase & Co. upped their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. UBS Group assumed coverage on NeuroPace in a research note on Tuesday. They set a “buy” rating and a $17.00 price target for the company. Finally, Wells Fargo & Company cut their price objective on NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $14.04 on Thursday. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.15. The stock has a 50 day moving average of $11.13 and a two-hundred day moving average of $8.52. The stock has a market cap of $419.07 million, a P/E ratio of -14.04 and a beta of 2.02.

Insider Buying and Selling at NeuroPace

In related news, major shareholder Ltd. Kck sold 223,991 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares of the company’s stock, valued at $28,726,105.25. This trade represents a 4.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.20% of the stock is owned by corporate insiders.

Institutional Trading of NeuroPace

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of NeuroPace during the 2nd quarter valued at about $111,000. Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 20.0% during the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after buying an additional 3,000 shares during the period. Barclays PLC grew its stake in NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.